High Tide invests 26M in Germany with majority acquisition of Remexian Pharma
High Tide has made a significant move in the German medical cannabis market by acquiring a majority stake in Remexian Pharma GmbH for €26 million. This acquisition is expected to lead to increased merger and acquisition activity in the sector, marking a notable expansion of High Tide's presence in Germany and indicating a trend towards industry consolidation.
High Tide has completed a transformative €26 million majority acquisition of Remexian Pharma GmbH, a move that is expected to spark increased merger and acquisition activity in the German medical cannabis market. The company stated that this transaction marks a significant expansion of its presence in Germany and signals a new wave of industry consolidation. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. High Tide Inc. published the original content used to generate this news brief on October 09, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
